|1.||Pietrzak, L: 2 articles (04/2009 - 09/2007)|
|2.||Buczko, W: 2 articles (04/2009 - 09/2007)|
|3.||Mogielnicki, A: 2 articles (04/2009 - 09/2007)|
|4.||Krausz, Kristopher W: 1 article (10/2014)|
|5.||Johnson, Caroline H: 1 article (10/2014)|
|6.||Pan, Yu-Zhuo: 1 article (10/2014)|
|7.||Bi, Hui-Chang: 1 article (10/2014)|
|8.||Yu, Ai-Ming: 1 article (10/2014)|
|9.||Gonzalez, Frank J: 1 article (10/2014)|
|10.||Jiang, Chang-Tao: 1 article (10/2014)|
09/01/2007 - "In the present study we have investigated the influence of N-methylnicotinamide on arterial thrombosis in normotensive and renovascular hypertensive rats. "
09/01/2007 - "N-methylnicotinamide inhibits arterial thrombosis in hypertensive rats."
09/01/2007 - "Our study shows that N-methylnicotinamide via production/release of prostacyclin inhibits arterial thrombosis development. "
09/01/2007 - "Indomethacin - an inhibitor of prostacyclin synthesis, completely abolished the antithrombotic and antiplatelet effect of N-methylnicotinamide, and the plasma level of 6-keto-PGF(1alpha) , prostacyclin metabolite, increased simultaneously with the inhibition of thrombus formation. "
09/01/2007 - "N-methylnicotinamide, but not nicotinamide, administered intravenously into renovascular hypertensive rats developing electrically induced arterial thrombosis caused dose-dependent decrease of thrombus weight, collagen-induced platelet aggregation and plasma antigen/activity of plasminogen activator inhibitor - 1, without changing of occlusion time, routine coagulation parameters and plasma activity of tissue plasminogen activator. "
|2.||Liver Cirrhosis (Hepatic Cirrhosis)
04/01/2001 - "The metabolism of nicotinamide in human liver cirrhosis: a study on N-methylnicotinamide and 2-pyridone-5-carboxamide production."
04/01/2001 - "Serum and urinary levels (mean +/- SEM) of N-methylnicotinamide and urinary excretion of 2-pyridone-5-carboxamide were measured in 10 healthy controls and 10 patients with liver cirrhosis in basal conditions and after a nicotinamide oral load (1.5 mg/kg body weight). "
01/01/1991 - "Pellagra diagnosis was made on the basis of the typical clinical skin picture, and low urinary excretion of N'methylnicotinamide and N'methyl-2-pyridone-5-carboxamide (reduced by 70 and 80%, respectively, compared with controls). "
08/01/1989 - "Upon admission the pellagra patients had low plasma Zn levels and low urinary excretion values of N'methylnicotinamide (N'MN) and N'methyl-2-pyridone-5-carboxamide (2-PYR) in relation to the control subjects (p less than 0.01). "
03/09/1963 - "THE ROLE OF MAIZE IN THE PATHOGENESIS OF PELLAGRA: EFFECT OF LEUCINE ON N'-METHYLNICOTINAMIDE EXCRETION IN HUMAN ADULTS."
01/01/1994 - "The basal serum levels of N-methyl-nicotinamide were significantly (p < 0.05) higher in patients with cirrhosis (Child A: median 34 ng/ml, 16th percentile 24, 84th percentile 61; Child B median 45, 16th percentile 34, 84th percentile 81) than in controls (median 22, 16th percentile 13, 85th percentile 28). "
10/01/1995 - "In human cirrhosis N-methylnicotinamide serum levels are higher than normal, in basal condition and after nicotinamide oral load. "
01/01/1994 - "After the nicotinamide load the urinary excretion and the time course of serum N-methyl-nicotinamide in cirrhosis were also higher (p < 0.05) than in controls (24 h urinary excretion = 66.2 mg +/- 5 S.D. "
01/01/1994 - "In seven controls and in nine patients with cirrhosis (5 Child A and 4 Child B), the serum levels and urinary excretion (5 and 24 h) of N-methyl-nicotinamide were also evaluated after oral administration of nicotinamide (1.5 mg/kg body weight). "
|3.||Biological Markers (Surrogate Marker)
|5.||Plasminogen Activator Inhibitor 1
|6.||1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
|10.||Tissue Plasminogen Activator (Alteplase)